It’s always tempting to buy beaten-down stocks based on promises of …
FDA approval
(NYSE:VRX) (TSE:VRX) is scheduled to be issuing its Q416 quarterly earnings data on Tuesday, February 28th. The fund owned 500,000 shares of the specialty pharmaceutical company's stock after selling 100,000 shares …
Levels
Over the course of the week the stock was up over 60%. Valeant shares closed Friday at $16.18. The 52-week trading range is $13.00 to $86.50, and the consensus price target is $22.39. Trevena Inc. (NASDAQ: TRVN) …
What a difference a week makes for Bill Ackman. After bleeding money …
Hedge Fund
Valeant's SILIQ drug is on schedule. Revenue potential for SILIQ starts in 2H/2017 and accelerates in 2018-19. A stock typically signals severe undervaluation when the company reports positive developments but the stock
psoriasis
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) call options are trading at …
Signal
Valeant Pharmaceuticals will report its Q4 earnings on February 28th. VRX stock remains a risky bet going into the earnings. The Quebec-based specialty pharma company is scheduled to report its Q4 and FY 2016 …
Valeant Pharmaceuticals